|
Nitrite testing in Excipients
|
|
2
|
439
|
August 17, 2025
|
|
MEGLUMINE (Methylglucamine)
|
|
27
|
3214
|
July 10, 2025
|
|
Nitrosamines excipient EDTA
|
|
3
|
307
|
June 12, 2025
|
|
Interferencia de matriz para cuantificación de NDBA
|
|
0
|
73
|
May 5, 2025
|
|
Can Ionized Air in Pharma Pose a Risk of Nitrite Formation
|
|
4
|
376
|
March 10, 2025
|
|
Impact of Antioxidant Excipients on N-nitrosamine Formation and Bioequivalence in Metformin Formulations - Pub
|
|
3
|
663
|
February 11, 2025
|
|
Low nitrite excipients
|
|
11
|
2804
|
November 27, 2024
|
|
Nitrosamnes in PMs & Excipients Questions
|
|
5
|
1080
|
November 22, 2024
|
|
Managing Nitrite Impurities: A Supplier-Manufacturer Approach to Mitigate Nitrosamine Risk
|
|
2
|
659
|
October 18, 2024
|
|
Primeros pasos para evaluar nitrosaminas en medicamentos
|
|
5
|
260
|
September 23, 2024
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
0
|
270
|
September 10, 2024
|
|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1671
|
September 5, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
441
|
August 29, 2024
|
|
IPEC Webinar on the role of excipients in determine N-nitrosamine risks
|
|
3
|
484
|
July 24, 2024
|
|
Parts per billion of nitrite in microcrystalline cellulose -Pub
|
|
3
|
1147
|
July 3, 2024
|
|
Risk analysis of nitrosamine impurities in liquid products (essences and flavors)
|
|
3
|
746
|
June 28, 2024
|
|
Insights from the Lhasa Limited and IPEC Europe Nitrites collaborative meeting
|
|
1
|
535
|
June 16, 2024
|
|
Lactose, Nitrosamine Risk?
|
|
35
|
3457
|
April 6, 2022
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
1115
|
June 4, 2024
|
|
N-nitroso cyclamate
|
|
9
|
725
|
March 15, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
524
|
March 13, 2024
|
|
Updated: IPEC Position Paper on Role of Excipients in Determining N-Nitrosamine Risks for Drug Products
|
|
3
|
1227
|
March 7, 2024
|
|
MCC with nitrite levels of 0.1 ppm or less
|
|
4
|
1385
|
March 4, 2024
|
|
A quick (dumb) question
|
|
10
|
1314
|
January 22, 2024
|
|
Low nitrile crosscarmellose sodium
|
|
0
|
435
|
November 6, 2023
|
|
Personal perspective on N-Nitrosamines and recent revision of guidelines
|
|
7
|
803
|
October 27, 2023
|
|
Variation requirements
|
|
2
|
455
|
October 2, 2023
|
|
Apixaban Drug Substance-Related Impurities (NDSRIs)
|
|
3
|
1608
|
September 15, 2023
|
|
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments
|
|
4
|
1320
|
September 7, 2023
|
|
FDA Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities
|
|
11
|
3899
|
July 27, 2023
|